These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27073470)

  • 41. Protective role of magnesium isoglycyrrhizinate in non-alcoholic fatty liver disease and the associated molecular mechanisms.
    Xu Q; Wang J; Chen F; Lin K; Zhu M; Chen L; Zhou X; Li C; Zhu H
    Int J Mol Med; 2016 Jul; 38(1):275-82. PubMed ID: 27220460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Curcumin decreases oleic acid-induced lipid accumulation via AMPK phosphorylation in hepatocarcinoma cells.
    Kang OH; Kim SB; Seo YS; Joung DK; Mun SH; Choi JG; Lee YM; Kang DG; Lee HS; Kwon DY
    Eur Rev Med Pharmacol Sci; 2013 Oct; 17(19):2578-86. PubMed ID: 24142602
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effects of PPAR-alpha activation on oleic acid-induced steatosis and expression of heme oxygenase-1 in HepG2 cells].
    Zhao JJ; Zhao LF; Yang H; Zhang L
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):218-21. PubMed ID: 23967745
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lotus Seedpod Extracts Reduced Lipid Accumulation and Lipotoxicity in Hepatocytes.
    Liu YT; Lai YH; Lin HH; Chen JH
    Nutrients; 2019 Nov; 11(12):. PubMed ID: 31795130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Downregulation of miR-192 causes hepatic steatosis and lipid accumulation by inducing SREBF1: Novel mechanism for bisphenol A-triggered non-alcoholic fatty liver disease.
    Lin Y; Ding D; Huang Q; Liu Q; Lu H; Lu Y; Chi Y; Sun X; Ye G; Zhu H; Wei J; Dong S
    Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Sep; 1862(9):869-882. PubMed ID: 28483554
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Leonurus japonicus Houtt Attenuates Nonalcoholic Fatty Liver Disease in Free Fatty Acid-Induced HepG2 Cells and Mice Fed a High-Fat Diet.
    Lee MR; Park KI; Ma JY
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29295591
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Artemisia capillaris formula inhibits hepatic steatosis via an miR‑122‑induced decrease in fatty acid synthase expression in vivo and in vitro.
    Liu L; Zhao J; Li Y; Wan Y; Lin J; Shen A; Xu W; Li H; Zhang Y; Xu J; Peng J; Hong Z
    Mol Med Rep; 2016 Jun; 13(6):4751-8. PubMed ID: 27081834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
    Long JK; Dai W; Zheng YW; Zhao SP
    Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
    Bozic M; Guzmán C; Benet M; Sánchez-Campos S; García-Monzón C; Gari E; Gatius S; Valdivielso JM; Jover R
    J Hepatol; 2016 Oct; 65(4):748-757. PubMed ID: 27245430
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells.
    Yin J; Luo Y; Deng H; Qin S; Tang W; Zeng L; Zhou B
    J Ethnopharmacol; 2014 May; 154(1):229-39. PubMed ID: 24735863
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease.
    Zhang H; Yang L; Wang Y; Huang W; Li Y; Chen S; Song G; Ren L
    Life Sci; 2020 Sep; 257():118090. PubMed ID: 32679144
    [TBL] [Abstract][Full Text] [Related]  

  • 52. IGFBP5 modulates lipid metabolism and insulin sensitivity through activating AMPK pathway in non-alcoholic fatty liver disease.
    Xiao Z; Chu Y; Qin W
    Life Sci; 2020 Sep; 256():117997. PubMed ID: 32585242
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.
    Liu Q; Pan R; Ding L; Zhang F; Hu L; Ding B; Zhu L; Xia Y; Dou X
    Int Immunopharmacol; 2017 Aug; 49():132-141. PubMed ID: 28577437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanism of the promotion of steatotic HepG2 cell apoptosis by cholesterol.
    Zhu C; Xie P; Zhao F; Zhang L; An W; Zhan Y
    Int J Clin Exp Pathol; 2014; 7(10):6807-13. PubMed ID: 25400762
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of daphnetin on lipid metabolism, insulin resistance and oxidative stress in OA‑treated HepG2 cells.
    Liu Y; Liao L; Chen Y; Han F
    Mol Med Rep; 2019 Jun; 19(6):4673-4684. PubMed ID: 30957185
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Nutraceutic Silybin Counteracts Excess Lipid Accumulation and Ongoing Oxidative Stress in an
    Vecchione G; Grasselli E; Cioffi F; Baldini F; Oliveira PJ; Sardão VA; Cortese K; Lanni A; Voci A; Portincasa P; Vergani L
    Front Nutr; 2017; 4():42. PubMed ID: 28971098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ganoderma Lucidum Polysaccharide Peptide Alleviates Hepatoteatosis via Modulating Bile Acid Metabolism Dependent on FXR-SHP/FGF.
    Zhong D; Xie Z; Huang B; Zhu S; Wang G; Zhou H; Lin S; Lin Z; Yang B
    Cell Physiol Biochem; 2018; 49(3):1163-1179. PubMed ID: 30196282
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative study of the modulation of fructose/sucrose-induced hepatic steatosis by mixed lipid formulations varying in unsaturated fatty acid content.
    Siddiqui RA; Xu Z; Harvey KA; Pavlina TM; Becker MJ; Zaloga GP
    Nutr Metab (Lond); 2015; 12():41. PubMed ID: 26583036
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atorvastatin promotes AMPK signaling to protect against high fat diet-induced non-alcoholic fatty liver in golden hamsters.
    Zhang B; Zhang C; Zhang X; Li N; Dong Z; Sun G; Sun X
    Exp Ther Med; 2020 Mar; 19(3):2133-2142. PubMed ID: 32104276
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.